According to Demis Hassabis, Isomorphic Labs has entered a cross-modality, multi-target research collaboration with Johnson & Johnson Innovation to combine its AI drug design engine with J&J’s drug development capabilities and address historically difficult to drug disease targets, source: Demis Hassabis on X. The partners aim to design novel molecules that might otherwise remain undiscovered, marking a significant push in digital biology and AI drug discovery, source: Demis Hassabis on X. The announcement did not disclose any cryptocurrency involvement or tokenization elements, so crypto traders should note that any market impact would hinge on future public milestones from the two companies, source: Demis Hassabis on X.